UP!

SGMO $5.97

SGMO target price
5.97
0
0
Sangamo BioSciences
Type
Public
Industry Biomedicine
Founder Edward O. Lanphier II
Headquarters Richmond, California, USA
Number of employees
84
Website http://www.sangamo.com

Sangamo BioSciences (NASDAQ: SGMO) is a clinical stage biopharmaceutical company involved in gene therapy that is researching ways of commercializing Zinc finger nucleases which modify a cell's DNA at an exact location thereby correcting or disrupting a specific gene.

Sangamo BioSciences' lead therapy, SB-728, is a potential functional cure for HIV/AIDS. SB-728 works by removing some of the immune cells from the patient's blood that HIV attacks. The blood is sent to a lab which applies the SB-728 treatment to the patient's immune cells. The treatment removes the protein gateway on the immune cells that HIV needs to infect. The treated cells are then infused back into the patient whereby they reproduce and take over as HIV attacks and kills the non-treated cells. The treated, resistant cells thereby control the HIV infection and thus cures the patient from opportunistic infections that result from HIV. Recent published data further support the company's ongoing progress which has been described as "a major step toward immunological functional control of HIV."

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q3 2022 2022-11-02 Future report Set alerts
Q2 2022 2022-08-04 -0.29 -0.29
Q1 2022 2022-05-05 -0.30 -0.30
Q4 2021 2022-02-24 -0.26 -0.26
Q3 2021 2021-11-04 -0.33 -0.33
Q2 2021 2021-08-05 -0.33 -0.33
Q1 2021 2021-05-04 -0.32 -0.32
Q4 2020 2021-02-24 -0.29 -0.29
Q3 2020 2020-11-04 0.00 0.00
Q2 2020 2020-08-05 -0.26 -0.26

Ratings

2016-06-09 Reiterated Rating Jefferies Group Buy $14.00
2016-05-06 Reiterated Rating Wedbush Outperform $30.00
2016-05-03 Initiated Coverage Wells Fargo Buy
2016-05-03 Initiated Coverage Wells Fargo & Co. Buy
2016-03-03 Reiterated Rating Wedbush Outperform $30.00
2016-02-10 Reiterated Rating Wedbush Outperform $30.00
2016-02-10 Reiterated Rating JPMorgan Chase & Co. Overweight $16.00
2016-01-04 Reiterated Rating Wedbush Outperform $30.00
2015-12-22 Reiterated Rating Wedbush Outperform $30.00
2015-12-17 Initiated Coverage Janney Montgomery Scott Buy $15.00
2015-12-08 Reiterated Rating Wedbush Buy $30.00
2015-12-03 Reiterated Rating JPMorgan Chase & Co. Buy $16.00
2015-12-03 Initiated Coverage Wells Fargo Outperform
2015-12-02 Reiterated Rating Wedbush Outperform $30.00
2015-10-23 Initiated Coverage Jefferies Group Buy $12.00 to $14.00
2015-09-28 Reiterated Rating Piper Jaffray Buy $17.00
2015-09-28 Reiterated Rating Piper Jaffray Cos. Buy $17.00
2015-09-11 Reiterated Rating Piper Jaffray Buy $17.00
2015-09-04 Reiterated Rating Cowen and Company Buy
2015-09-02 Lower Price Target Jefferies Group Buy $22.00 to $12.00
2015-09-02 Reiterated Rating JPMorgan Chase & Co. Buy $22.00 to $16.00
2015-09-02 Reiterated Rating Wedbush Buy $30.00
2015-08-07 Reiterated Rating JPMorgan Chase & Co. Overweight $22.00
2015-08-07 Reiterated Rating Wedbush Outperform $30.00
2015-06-05 Reiterated Rating Piper Jaffray Overweight $17.00
2015-05-19 Reiterated Rating BMO Capital Markets Outperform $19.00
2015-05-14 Set Price Target Wedbush Buy $30.00
2015-04-23 Set Price Target Wedbush Buy $30.00
2015-04-22 Initiated Coverage BMO Capital Markets Outperform $19.00
2015-03-01 Reiterated Rating Wedbush Outperform $30.00
2015-02-11 Reiterated Rating Wedbush Outperform $30.00
2015-02-04 Initiated Coverage Wedbush Buy $29.00
2015-01-27 Initiated Coverage Wedbush Buy $29.00
2015-01-12 Reiterated Rating Wedbush Outperform $29.00
2014-09-23 Initiated Coverage Jefferies Group Buy $22.00
2014-09-10 Boost Price Target Wedbush $27.00 to $28.00
2014-08-01 Initiated Coverage JPMorgan Chase & Co. Overweight $22.00
2014-03-12 Boost Price Target JMP Securities Outperform $22.00 to $27.00
2014-01-09 Boost Price Target Wedbush $22.00
2013-11-05 Boost Price Target Wedbush Outperform $13.00 to $15.00
2013-10-23 Boost Price Target Lazard Capital Markets Buy $16.00 to $20.00
2013-05-03 Initiated BioLogic Equity Research Sell
2011-02-23 Reiterated JMP Securities Mkt Outperform $9 to $12
2009-10-19 Initiated Brean Murray Sell $4
2009-10-07 Reiterated Leerink Swann Outperform $9 to $11
2009-08-25 Reiterated JMP Securities Mkt Outperform $13 to $15
2009-04-14 Downgrade Cantor Fitzgerald Buy to Hold
2009-02-23 Reiterated Leerink Swann Outperform $6 to $9
2009-02-05 Upgrade Merriman Curhan Ford Neutral to Buy
2008-11-20
2008-11-11 Reiterated Brean Murray Sell $4 to $2
2008-11-11 Downgrade Piper Jaffray Buy to Sell
2008-11-11 Downgrade Merriman Curhan Ford Buy to Neutral
2008-10-16 Initiated Merriman Curhan Ford Buy
2008-08-26 Reiterated Leerink Swann Outperform $18 to $17
2008-05-29 Initiated Brean Murray Sell $5
2008-05-01 Reiterated JMP Securities Mkt Outperform $18 to $24
2008-02-06 Reiterated JMP Securities Strong Buy $30 to $18
2007-12-05 Reiterated Cantor Fitzgerald Buy $17 to $27
2016-06-09 Reiterated Rating Jefferies Group Buy $14.00
2016-05-06 Reiterated Rating Wedbush Outperform $30.00
2016-05-03 Initiated Coverage Wells Fargo Buy
2016-05-03 Initiated Coverage Wells Fargo & Co. Buy
2016-03-03 Reiterated Rating Wedbush Outperform $30.00

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
RA CAPITAL MANAGEMENT, LLC Former 10% Owner. 5.40%  (3683000) ACHN / ARDM / BSTC / DRNA / DSCI / SGMO /
LANPHIER EDWARD O II President & CEO 1.72%  (1175094) SGMO /
LARSON JOHN WILLIAM 0.31%  (214660) SGMO / WAGE /
Wolff Henry Ward Exec VP & CFO 0.30%  (206829) ABIO / CALA / PTLA / SGMO /
NICHOL GEOFFREY Executive Vice President, R&D 0.23%  (159676) SGMO /
Gregory Philip D Vice President, Research & CSO 0.17%  (116410) BLUE / SGMO /
ANDO DALE G VP, Therapeutic Dev. & CMO 0.16%  (107328) SGMO /
Macrae Sandy President and CEO 0.05%  (31500) SGMO /
Herberts Curt A. III Senior VP & CBO 0.02%  (14625) SGMO /
Mento Steven J 0.02%  (11832) CNAT / SGMO /
Conner Edward R. Sr. VP & Chief Medical Officer 0.01%  (8125) SGMO /
Yi Kathy Senior VP & CFO 0.01%  (7250) SGMO /